



Biocon Limited
20th KM, Hosur Road
Electronic City
Bangalore 560 100, India
T 91 80 2808 2808
F 91 80 2852 3423

CIN : L24234KA1978PLC003417

www.biocon.com

BIO/SECL/TG/2026-27/21

May 11, 2026

To The Manager, BSE Limited Department of Corporate Services Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400 001	To The Manager, National Stock Exchange of India Limited Corporate Communication Department Exchange Plaza, Bandra Kurla Complex Mumbai – 400 050
Scrip Code - 532523	Scrip Symbol - BIOCON

Subject: Company Statement

Dear Sir/Madam,

Please find enclosed Company Statement w.r.t. **“Biocon Pharma Limited Receives Health Canada Approval for Micafungin for Injection, USP, 50 MG and 100 MG”**.

The above information will also be available on the website of the Company at www.biocon.com.

Kindly take the same on record and acknowledge.

Thanking You,

Yours faithfully,

For **Biocon Limited**

Rajesh U. Shanoy
Company Secretary and Compliance Officer
M. No.: ACS 16328

Encl: Company Statement

NOTIFICATION TO STOCK EXCHANGE**COMPANY STATEMENT****Biocon Pharma Limited Receives Health Canada Approval
for Micafungin for Injection, USP, 50 MG and 100 MG**

Bengaluru, Karnataka, India, May 11, 2026

Biocon Pharma Limited, a subsidiary of Biocon Limited, today announced that it has received approval from Health Canada for micafungin for injection, USP, 50 mg and 100 mg. The approved product is indicated for use in adults and children four months and older for treatment of patients with Candidemia, Acute Disseminated Candidiasis, Candida Peritonitis and Abscesses infections; treatment of patients with esophageal candidiasis; and prophylaxis of Candida infections in patients undergoing hematopoietic stem cell transplantation.

The approval will further strengthen Biocon's integrated biosimilars and generics portfolio.